2008/2009 Biotechnology Research Review

Published by: BCC Research

Published: Jul. 1, 2009 - 218 Pages

Table of Contents

2008/2009 BIOTECHNOLOGY RESEARCH REVIEW

FOREWORD

CHAPTER ONE: SYNTHETIC BIOLOGY: EMERGING GLOBAL MARKETS (BIO066A)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

INTENDED AUDIENCE

SCOPE OF REPORT

METHODOLOGY

INFORMATION SOURCES

RELATED BCC REPORTS

ANALYST CREDENTIALS

SUMMARY

TABLE 1 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY INDUSTRY, THROUGH 2013 ($ MILLIONS)

FIGURE 1 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY INDUSTRY, 2006-2013 ($ MILLIONS)

OVERVIEW

SYNTHETIC BIOLOGY TECHNOLOGIES COVERED IN THIS REPORT

TABLE 2 SCOPE OF THIS REPORT

WHAT IS SYNTHETIC BIOLOGY?

DEVELOPMENT STAGE OF SYNTHETIC BIOLOGY

FORCES DRIVING SYNTHETIC BIOLOGY MARKET GROWTH

TABLE 3 SYNTHETIC BIOLOGY GROWTH DRIVING FORCES

GLOBAL MARKET POTENTIAL FOR SYNTHETIC BIOLOGY PRODUCTS

TABLE 4 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY END USER, THROUGH 2013 ($ MILLIONS)

TABLE 5 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED ENERGY MARKET BY FUEL TYPE, THROUGH 2013 ($ MILLIONS)

LIFE CYCLE STATUS OF SYNTHETIC BIOLOGY TECHNOLOGIES

TABLE 6 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY LIFE CYCLE STAGE

THE SYNTHETIC BIOLOGY INDUSTRY

TABLE 7 SYNTHETIC BIOLOGY KEY COMPETITORS BY MARKET FOCUS

CHAPTER TWO: COMMERCIAL AMINO ACIDS (BIO007H)

INTRODUCTION

STUDY OBJECTIVES

REASONS FOR DOING THIS STUDY

INTENDED AUDIENCE

SCOPE OF REPORT

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC REPORTS

BCC ON-LINE SERVICES

DISCLAIMER

SUMMARY

TABLE 8 U.S. AMINO ACIDS MARKET SIZE, THROUGH 2013 ($ MILLIONS)

FIGURE 2 U.S. AMINO ACIDS MARKET SIZE, 2005-2013 ($ MILLIONS)

OVERVIEW OF AMINO ACIDS

TABLE 9 THE PROTEIN AMINO ACIDS

COMMERCIAL INTERESTS

TABLE 10 MAJOR COMMERCIAL APPLICATIONS

Feed Fortification

Food Flavoring Agents

Specialty Uses

Dietary Needs

TABLE 11 THE “ESSENTIAL” AMINO ACIDS

BIOLOGIC VALUE OF AMINO ACID MIXTURES

TABLE 12 PROTEIN VALUE OF SELECTED FOODS

RECOMMENDED DAILY ALLOWANCE

Amino Acid Metabolism

PROPERTIES

CHEMICAL STRUCTURE

TABLE 13 CHEMICAL STRUCTURE OF AMINO ACIDS

ISOLATION/ANALYSIS

Microbiological Assay

Chromatographic Separation

PRODUCTION TECHNOLOGY

TABLE 14 AMINO ACIDS BY PRODUCTION METHODS

Extraction

Fermentation

Microbiological Processes

TABLE 15 AMINO ACID PRODUCTION BY FERMENTATION

Chemical Synthesis

Enzymatic Conversion

REGULATION

Federal Drug Administration (FDA)

U.S. Pharmacopoeia (U.S.P)

TABLE 16 U.S.P VERIFIED AMINO ACID PRODUCTS

The Bush Administration

STRUCTURE OF THE INDUSTRY AND ITS COMPETITIVE ASPECTS

TABLE 17 MAJOR AMINO ACID PRODUCERS

FIGURE 3 SHARE OF GLOBAL AMINO ACIDS MARKET, 2008 (%)

IMPORTANT STRATEGIES

MARKET SHARE

TABLE 18 LEADING PRODUCERS, BY TYPE, OF AMINO ACID

FIGURE 4 MARKET SHARE OF MAJOR PLAYERS, 2008 (%)

MARKET FORCES

CHAPTER THREE: MONOCLONAL THERAPEUTICS AND COMPANION DIAGNOSTIC PRODUCTS (BIO016G)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THIS STUDY

SCOPE OF REPORT

INTENDED AUDIENCE

METHODOLOGY

INFORMATION SOURCES

ABOUT THE AUTHOR

RELATED BCC WORK CREDENTIALS

EXECUTIVE SUMMARY

TABLE 19 WORLDWIDE SALES OF MONOCLONAL THERAPEUTIC AND COMPANION DIAGNOSTICS, THROUGH 2012 ($ BILLIONS)

FIGURE 5 WORLDWIDE SALES OF MONOCLONAL THERAPEUTIC AND COMPANION DIAGNOSTICS, 2005-2012 ($ BILLIONS)

MAB GROWTH IN THERAPEUTICS

Pharma Moves In

MAB GROWTH IN DIAGNOSTICS

Key Drivers and Challenges

Significant Trends

OVERVIEW

TABLE 20 BIOPHARMACEUTICAL CATEGORIES

TABLE 21 MONOCLONAL ANTIBODIES APPROVED FOR DISEASE THERAPY*

FIGURE 6 COMPOSITION OF COMMERCIALIZED ANTIBODIES BY TYPE, 2007 AND 2012 (%)

FIGURE 7 ANTIBODY ILLUSTRATED

MAB TECHNOLOGY: BEGINNINGS AND MOVEMENTS

TABLE 22 TIMELINE FOR MAB DEVELOPMENT

Moving Towards Humanization

ANTIBODY TECHNOLOGY TYPES

Humanization

TABLE 23 WORLDWIDE FORECAST OF THERAPEUTIC MONOCLONAL ANTIBODIES, BY TYPE, THROUGH 2012 ($ BILLIONS)

Superhumanization

Smart Technology

TABLE 24 SMART TECHNOLOGY ROYALTIES BY LICENSEE AND PRODUCT AS A PERCENTAGE OF TOTAL ROYALTY REVENUE: EXAMPLE OF TECHNOLOGY ROYALTY POTENTIAL (%)

Fully Human Technology

Phage Display

Crucell’s Per.C6 and Mabstract

Transgenic Mice

TABLE 25 TRANSGENIC TECHNOLOGIES

Emerging Antibody Technology Types

Fragments

Single Chain Antibodies

Bispecific Antibodies

Conjugation

TABLE 26 LEADING CONJUGATION TECHNOLOGIES

TECHNOLOGY RELATED ISSUES AND CHALLENGES

Optimization

Adjusting Glycosylation

TABLE 27 ANTIBODY TECHNOLOGY BEHIND COMMERCIALIZED MABS

MANUFACTURING

LEGALITY AND INTELLECTUAL PROPERTY

TABLE 28 CAT’S PHAGE AND RIBOSOME DISPLAY PATENTS

PHARMACEUTICAL AND BIOTECHNOLOGY LANDSCAPE

TABLE 29 PHARMA’S MAB-RELATED ACQUISITIONS

FIGURE 8 THE SYNERGY OF PHARMA AND BIOTECH

TABLE 30 GLOBAL SNAPSHOT: BIOTECHNOLOGY INDUSTRY, 2006

CHAPTER FOUR: ENVIRONMENTAL MARKETS FOR BIOTECHNOLOGY (BIO019B)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR STUDY AND IMPORTANCE

INTENDED AUDIENCE

SCOPE OF REPORT

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED REPORTS

SUMMARY

TABLE 31 U.S. VALUE OF ENVIRONMENTAL BIOTECHNOLOGY PRODUCTS FOR WASTE TREATMENT, THROUGH 2013 ($ MILLIONS)

FIGURE 9 MARKET SHARE BY PRODUCT TYPE, 2008 (%)

CHAPTER FIVE: PROTEIN DRUGS: GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES (BIO021C)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

INTENDED AUDIENCE

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED REPORTS

SUMMARY

TABLE 32 GLOBAL MARKET FOR PROTEIN THERAPEUTICS, THROUGH 2013 ($ MILLIONS)

FIGURE 10 GLOBAL MARKET FOR PROTEIN THERAPEUTICS, 2007-2013 ($ MILLIONS)

CHAPTER SIX: BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS (BIO022E)

INTRODUCTION

STUDY BACKGROUND

STUDY GOAL AND OBJECTIVES

INTENDED AUDIENCE

SCOPE OF REPORT

Scope of Report (Continued)

METHODOLOGY AND INFORMATION SOURCES

COMMERCIAL DRUGS

DEVELOPMENTAL DRUGS

TABLE 33 FDA APPROVAL PROCESS FOR NEW DRUGS

ANALYST CREDENTIALS

RELATED BCC PUBLICATIONS

SUMMARY

TABLE 34 GLOBAL FORECAST FOR BOTANICAL* AND PLANTDERIVED DRUGS, THROUGH 2013 ($ BILLIONS)

FIGURE 11 GLOBAL FORECAST FOR BOTANICAL* AND PLANTDERIVED DRUGS, 2006-2013 ($ BILLIONS)

OVERVIEW

BRIEF HISTORY OF PLANT-DERIVED MEDICINES

TABLE 35 KEY DATES IN BOTANICAL MEDICINE

TABLE 36 WELL KNOWN PLANT-DERIVED DRUGS

OPPORTUNITY LIES BEYOND WHAT’S KNOWN

FIGURE 12 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED COMPOUNDS IN U.S. (2000-2005)* (%)

KEY DRIVERS

KEY CHALLENGES

SIGNS OF INDUSTRY INVESTMENT

TABLE 37 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT

TABLE 38 KEY SIGNS OF INVESTMENT IN BOTANICAL AND OTHER PLANT-DERIVED DRUGS

BOTANICAL DRUGS DEFINED

UNDERSTANDING THE REGULATORY PROCESS

TABLE 39 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS MEDICINALLY

THE FIRST APPROVED BOTANICAL

A GROWING PIPELINE

FIGURE 13 INDS IN THE FDA BY THERAPEUTIC AREA (NUMBER)

OVERALL PHARMA LANDSCAPE

TABLE 40 TOP PHARMA COMPANIES BY REVENUE, 2007 ($ BILLIONS)

MAJOR CLASSES OF PLANT DRUGS

Terpenes and Steroids

Terpenes

Steroids

Alkaloids and Glycosides

Alkaloids

• Ergot Alkaloids

• Morphine Alkaloids

• Vinca Alkaloids

Glycosides

• Cardiac Glycosides

• Anthraglycosides

Phenols

E. Cava Algae

Flavonoids

• Resveratrol

Coumarin

Catechins

Proanthocyanidins

INTELLECTUAL PROPERTY

PRODUCTION

MOVING PRODUCTION FORWARD

ARTEMISININ: A CASE STUDY

SUPPLY AND LEGAL ISSUES

TABLE 41 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANTBASED MEDICINALS

DRUG DEVELOPMENT AND MANUFACTURE

TABLE 42 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES

CHAPTER SEVEN: STEM CELL TECHNOLOGY: CURRENT APPLICATIONS AND FUTURE DIRECTIONS (BIO035C)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

INTENDED AUDIENCE

INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC REPORTS

SUMMARY

TABLE 43 U.S. MARKET FOR STEM CELLS IN REGENERATIVE MEDICINE REVENUE, THROUGH 2012 ($ MILLIONS)

FIGURE 14 U.S. MARKET FOR STEM CELLS IN REGENERATIVE MEDICINE REVENUE, 2005-2012 ($ MILLIONS)

INTRODUCTION TO STEM CELLS TECHNOLOGY IN REGENERATIVE MEDICINE MARKET

STEM CELLS IN CELLULAR THERAPEUTICS

FIGURE 15 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN CELLULAR THERAPEUTICS

TABLE 44 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, THROUGH 2012 ($ MILLIONS)

FIGURE 16 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND EMBRYONIC STEM CELLS, 2005-2012 ($ MILLIONS)

Stem Cells in Cellular Therapeutics towards Engineering Tissue in Vitro for Transplantation

FIGURE 17 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN ENGINEERING TISSUE FOR TRANSPLANTATION

THERAPEUTIC STEM CELL BANKING

FIGURE 18 FLOW DIAGRAM FOR PROCESS OF THERAPEUTIC BANKING OF STEM CELLS

TABLE 45 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING, THROUGH 2012 ($ MILLIONS)

FIGURE 19 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC STEM CELL BANKING, 2005-2012 ($ MILLIONS)

CHAPTER EIGHT: RNA INTERFERENCE IN THE POST-GENOMIC ERA: MARKETS AND TECHNOLOGIES (BIO062A)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

INTENDED AUDIENCE

SCOPE OF REPORT

METHODOLOGY

INFORMATION SOURCES

RELATED BCC REPORTS

ANALYST CREDENTIALS

SUMMARY

TABLE 46 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY MARKET SEGMENT, THROUGH 2013 ($ MILLIONS)

FIGURE 20 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY MARKET SEGMENT, 2006-2013 ($ MILLIONS)

OVERVIEW

INTRODUCTION

CONVERGENCE OF POST GENOME TECHNOLOGIES

TABLE 47 POST GENOME ENABLING TOOLS

TABLE 48 NEW PARADIGM OF RNA INTERFERENCE

MARKET POTENTIAL OF RNA INTERFERENCE-BASED PRODUCTS

GLOBAL RNAI MARKET FORECAST

TABLE 49 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY MARKET SEGMENT, THROUGH 2013 ($ MILLIONS)

GLOBAL RNAI RESEARCH TOOLS MARKET

TABLE 50 GLOBAL VALUE OF RNA INTERFERENCE RESEARCH TOOLS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS)

TABLE 51 GLOBAL VALUE OF RNA INTERFERENCE DRUG MARKET, BY CLASS, THROUGH 2013 ($ MILLIONS)

GROWTH DRIVING FORCES IN RNA INTERFERENCE MARKETS

TABLE 52 PRIMARY FORCES DRIVING RNA INTERFERENCE GROWTH

RNA INTERFERENCE: BUILDING ON ANTISENSE TECHNOLOGIES

TABLE 53 KEY ANTISENSE CONTRIBUTIONS TO RNA INTERFERENCE

APPLICATIONS OF RNA INTERFERENCE

RNA INTERFERENCE AS A GENE KNOCKDOWN TECHNOLOGY

RNA INTERFERENCE AS A BIOMARKER

RNA INTERFERENCE IN THERAPEUTICS

RNA INTERFERENCE IN AGRICULTURE

THE RNA INTERFERENCE INDUSTRY

RNA INTERFERENCE TECHNOLOGIES

INTRODUCTION

ROLE OF MESSENGER RNA IN PROTEIN PRODUCTION

FIGURE 21 ROLE OF MESSENGER RNA IN PROTEIN PRODUCTION

TABLE 54 BASIC STEPS IN PROTEIN PRODUCTION

CHAPTER NINE: DNA DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS (BIO063A)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

INTENDED AUDIENCE

METHODOLOGY AND INFORMATION SOURCES

ANALYST CREDENTIALS

RELATED BCC REPORTS

SUMMARY

TABLE 55 GLOBAL MARKET FOR CLINICAL DNA DIAGNOSTICS, BY SEGMENT, THROUGH 2013 ($ MILLIONS)

FIGURE 22 GLOBAL MARKET FOR CLINICAL DNA DIAGNOSTICS, BY SEGMENT, 2005-2013 ($ MILLIONS)

OVERVIEW

INTRODUCTION TO GENOMIC DIAGNOSTICS

EXPRESSION PROFILING AND DISEASE

EXPRESSION PROFILING AND INFECTIOUS DISEASE

DNA SEQUENCING FOR GENOTYPING AND DIAGNOSIS

CLINICAL PHARMACOLOGY

MUTATION DETECTION AND GENOTYPING FOR SPECIFIC GENES

IDENTIFICATION OF NEW DISEASE GENES

REGULATORY FACTORS

SUCCESSES AND LIMITATIONS OF GENETIC TESTING

REGULATORY POLICIES

FOOD AND DRUG ADMINISTRATION: NEW GUIDELINES

INTERNAL STANDARDS FOR DNA DIAGNOSTICS

INSURANCE

MARKETING DIRECTLY TO CONSUMERS

MARKET FOR CLINICAL DNA DIAGNOSTICS, BY PRODUCT

TABLE 56 GLOBAL MARKET FORECAST FOR DNA DIAGNOSTICS PRODUCTS, THROUGH 2013 ($ MILLIONS)

FIGURE 23 GLOBAL MARKET FORECAST FOR DNA DIAGNOSTICS PRODUCTS, 2005-2013 ($ MILLIONS)

FIGURE 24 GLOBAL DNA DIAGNOSTICS MARKET, BY PRODUCT SHARE, 2008 (%)

FIGURE 25 GLOBAL DNA DIAGNOSTICS MARKET, BY PRODUCT SHARE, 2013 (%)

CHAPTER TEN: BIOLOGIC IMAGING REAGENTS: TECHNOLOGIES AND GLOBAL MARKETS (BIO064A)

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

INTENDED AUDIENCE

SCOPE OF REPORT

METHODOLOGY

INFORMATION SOURCES

RELATED BCC REPORTS

ANALYST CREDENTIALS

SUMMARY

TABLE 57 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TYPE, THROUGH 2013 ($ MILLIONS)

FIGURE 26 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TYPE, 2006-2013 ($ MILLIONS)

OVERVIEW

INTRODUCTION

BIOLOGIC IMAGING TECHNOLOGIES COVERED IN THIS REPORT

TABLE 58 SCOPE OF THIS REPORT

MARKET POTENTIAL OF BIOLOGIC REAGENTS PRODUCTS

TABLE 59 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY, THROUGH 2013 ($ MILLIONS)

TABLE 60 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET, THROUGH 2013 ($ MILLIONS)

FORCES DRIVING BIOLOGIC IMAGING REAGENTS INDUSTRY GROWTH

TABLE 61 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES

LIFE CYCLE STATUS OF BIOLOGIC IMAGING REAGENTS TECHNOLOGIES

TABLE 62 LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS

THE BIOLOGIC IMAGING REAGENTS INDUSTRY

TABLE 63 BIOLOGIC IMAGING REAGENTS KEY COMPETITORS

LIST OF TABLES

TABLE 1 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY

INDUSTRY, THROUGH 2013 ($ MILLIONS)

TABLE 2 SCOPE OF THIS REPORT

TABLE 3 SYNTHETIC BIOLOGY GROWTH DRIVING FORCES

TABLE 4 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY END

USER, THROUGH 2013 ($ MILLIONS)

TABLE 5 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED

ENERGY MARKET BY FUEL TYPE, THROUGH 2013 ($ MILLIONS)

TABLE 6 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY LIFE

CYCLE STAGE

TABLE 7 SYNTHETIC BIOLOGY KEY COMPETITORS BY MARKET

FOCUS

TABLE 8 U.S. AMINO ACIDS MARKET SIZE, THROUGH 2013 ($

MILLIONS)

TABLE 9 THE PROTEIN AMINO ACIDS

TABLE 10 MAJOR COMMERCIAL APPLICATIONS

TABLE 11 THE “ESSENTIAL” AMINO ACIDS

TABLE 12 PROTEIN VALUE OF SELECTED FOODS

TABLE 13 CHEMICAL STRUCTURE OF AMINO ACIDS

TABLE 14 AMINO ACIDS BY PRODUCTION METHODS

TABLE 15 AMINO ACID PRODUCTION BY FERMENTATION

TABLE 16 U.S.P VERIFIED AMINO ACID PRODUCTS

TABLE 17 MAJOR AMINO ACID PRODUCERS

TABLE 18 LEADING PRODUCERS, BY TYPE, OF AMINO ACID

TABLE 19 WORLDWIDE SALES OF MONOCLONAL THERAPEUTIC

AND COMPANION DIAGNOSTICS, THROUGH 2012 ($ BILLIONS)

TABLE 20 BIOPHARMACEUTICAL CATEGORIES

TABLE 21 MONOCLONAL ANTIBODIES APPROVED FOR DISEASE

THERAPY

TABLE 22 TIMELINE FOR MAB DEVELOPMENT

TABLE 23 WORLDWIDE FORECAST OF THERAPEUTIC MONOCLONAL

ANTIBODIES, BY TYPE, THROUGH 2012 ($ BILLIONS)

TABLE 24 SMART TECHNOLOGY ROYALTIES BY LICENSEE AND

PRODUCT AS A PERCENTAGE OF TOTAL ROYALTY REVENUE:

EXAMPLE OF TECHNOLOGY ROYALTY POTENTIAL (%)

TABLE 25 TRANSGENIC TECHNOLOGIES

TABLE 26 LEADING CONJUGATION TECHNOLOGIES

TABLE 27 ANTIBODY TECHNOLOGY BEHIND COMMERCIALIZED

MABS

TABLE 28 CAT’S PHAGE AND RIBOSOME DISPLAY PATENTS

TABLE 29 PHARMA’S MAB-RELATED ACQUISITIONS

TABLE 30 GLOBAL SNAPSHOT: BIOTECHNOLOGY INDUSTRY*

TABLE 31 U.S. VALUE OF ENVIRONMENTAL BIOTECHNOLOGY

PRODUCTS FOR WASTE TREATMENT, THROUGH 2013 ($

MILLIONS)

TABLE 32 GLOBAL MARKET FOR PROTEIN THERAPEUTICS,

THROUGH 2013 ($ MILLIONS)

TABLE 33 FDA APPROVAL PROCESS FOR NEW DRUGS

TABLE 34 GLOBAL FORECAST FOR BOTANICAL* AND PLANTDERIVED

DRUGS, THROUGH 2013 ($ BILLIONS)

TABLE 35 KEY DATES IN BOTANICAL MEDICINE

TABLE 36 WELL KNOWN PLANT-DERIVED DRUGS

TABLE 37 SWOT ANALYSIS ON BOTANICAL DRUG DEVELOPMENT

TABLE 38 KEY SIGNS OF INVESTMENT IN BOTANICAL AND OTHER

PLANT-DERIVED DRUGS

TABLE 39 DISTINCTIONS AMONG PRODUCTS THAT USE PLANTS

MEDICINALLY

TABLE 40 TOP PHARMA COMPANIES BY REVENUE, 2007 ($

BILLIONS)

TABLE 41 MAJOR PRODUCERS OF RAW MATERIALS FOR PLANTBASED

MEDICINALS

TABLE 42 KEY COMPANIES WITH NATURAL PRODUCT LIBRARIES

TABLE 43 U.S. MARKET FOR STEM CELLS IN REGENERATIVE

MEDICINE REVENUE, THROUGH 2012 ($ MILLIONS)

TABLE 44 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN

CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND

EMBRYONIC STEM CELLS, THROUGH 2012 ($ MILLIONS)

TABLE 45 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC

STEM CELL BANKING, THROUGH 2012 ($ MILLIONS)

TABLE 46 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY

MARKET SEGMENT, THROUGH 2013 ($ MILLIONS)

TABLE 47 POST GENOME ENABLING TOOLS

TABLE 48 NEW PARADIGM OF RNA INTERFERENCE

TABLE 49 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY

MARKET SEGMENT, THROUGH 2013 ($ MILLIONS)

TABLE 50 GLOBAL VALUE OF RNA INTERFERENCE RESEARCH

TOOLS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS)

TABLE 51 GLOBAL VALUE OF RNA INTERFERENCE DRUG MARKET,

BY CLASS, THROUGH 2013 ($ MILLIONS)

TABLE 52 PRIMARY FORCES DRIVING RNA INTERFERENCE

GROWTH

TABLE 53 KEY ANTISENSE CONTRIBUTIONS TO RNA

INTERFERENCE

TABLE 54 BASIC STEPS IN PROTEIN PRODUCTION

TABLE 55 GLOBAL MARKET FOR CLINICAL DNA DIAGNOSTICS, BY

SEGMENT, THROUGH 2013 ($ MILLIONS)

TABLE 56 GLOBAL MARKET FORECAST FOR DNA DIAGNOSTICS

PRODUCTS, THROUGH 2013 ($ MILLIONS)

TABLE 57 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY

TYPE, THROUGH 2013 ($ MILLIONS)

TABLE 58 SCOPE OF THIS REPORT

TABLE 59 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY

TECHNOLOGY, THROUGH 2013 ($ MILLIONS)

TABLE 60 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY

END USER MARKET, THROUGH 2013 ($ MILLIONS)

TABLE 61 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING

FORCES

TABLE 62 LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS

TABLE 63 BIOLOGIC IMAGING REAGENTS KEY COMPETITORS

LIST OF FIGURES

FIGURE 1 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY

INDUSTRY, 2006-2013 ($ MILLIONS)

FIGURE 2 U.S. AMINO ACIDS MARKET SIZE, 2005-2013 ($ MILLIONS)

FIGURE 3 SHARE OF GLOBAL AMINO ACIDS MARKET, 2008 (%)

FIGURE 4 MARKET SHARE OF MAJOR PLAYERS, 2008 (%)

FIGURE 5 WORLDWIDE SALES OF MONOCLONAL THERAPEUTIC

AND COMPANION DIAGNOSTICS, 2005-2012 ($ BILLIONS)

FIGURE 6 COMPOSITION OF COMMERCIALIZED ANTIBODIES BY

TYPE, 2007 AND 2012 (%)

FIGURE 7 ANTIBODY ILLUSTRATED

FIGURE 8 THE SYNERGY OF PHARMA AND BIOTECH

FIGURE 9 MARKET SHARE BY PRODUCT TYPE, 2008 (%)

FIGURE 10 GLOBAL MARKET FOR PROTEIN THERAPEUTICS, 2007-

2013 ($ MILLIONS)

FIGURE 11 GLOBAL FORECAST FOR BOTANICAL* AND PLANTDERIVED

DRUGS, 2006- 2013 ($ BILLIONS)

FIGURE 12 COMPOSITION OF FDA-APPROVED NATURAL-DERIVED

COMPOUNDS IN U.S. (2000-2005)* (%)

FIGURE 13 INDS IN THE FDA BY THERAPEUTIC AREA (NUMBER)

FIGURE 14 U.S. MARKET FOR STEM CELLS IN REGENERATIVE

MEDICINE REVENUE, 2005-2012 ($ MILLIONS)

FIGURE 15 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN

CELLULAR THERAPEUTICS

FIGURE 16 PROJECTED U.S. GROWTH TREND FOR STEM CELLS IN

CELL-BASED THERAPEUTICS FOR HUMAN ADULT AND

EMBRYONIC STEM CELLS, 2005-2012 ($ MILLIONS)

FIGURE 17 FLOW DIAGRAM OF PROCESS USING STEM CELLS IN

ENGINEERING TISSUE FOR TRANSPLANTATION

FIGURE 18 FLOW DIAGRAM FOR PROCESS OF THERAPEUTIC

BANKING OF STEM CELLS

FIGURE 19 PROJECTED U.S. GROWTH TREND FOR THERAPEUTIC

STEM CELL BANKING, 2005-2012 ($ MILLIONS)

FIGURE 20 GLOBAL VALUE OF RNA INTERFERENCE MARKET BY

MARKET SEGMENT, 2006-2013 ($ MILLIONS)

FIGURE 21 ROLE OF MESSENGER RNA IN PROTEIN PRODUCTION

FIGURE 22 GLOBAL MARKET FOR CLINICAL DNA DIAGNOSTICS, BY

SEGMENT, 2008-2013 ($ MILLIONS)

FIGURE 23 GLOBAL MARKET FORECAST FOR DNA DIAGNOSTICS

PRODUCTS, 2005-2013 ($ MILLIONS)

FIGURE 24 GLOBAL DNA DIAGNOSTICS MARKET, BY PRODUCT

SHARE, 2008 (%)

FIGURE 25 GLOBAL DNA DIAGNOSTICS MARKET, BY PRODUCT

SHARE, 2013 (%)

FIGURE 26 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY

TYPE, 2006-2013 ($ MILLIONS)

Abstract

• Synthetic Biology
• Commercial Amino Acids
• Monoclonal Therapeutics and Companion Diagnostic Products
• Environmental Markets for Biotechnology
• Protein Drugs
• Botanical and Plant-derived Drugs
• Stem Cells
• RNA Interference
• DNA Diagnostics
• Biologic Imaging Reagents

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.